Johnson & Johnson reportedly looking to buy Ollin Biosciences for up to $3.4 billion
JNJ•Johnson & Johnson is reportedly poised to buy privately held eye disease drug developer Ollin Biosciences for up to $3.4 billion. The deal under discussion could include $2.2 billion upfront and up to $1.2 billion in milestone payments.
1. Potential deal terms
Johnson & Johnson could pay Ollin Biosciences’ backers $2.2 billion in upfront cash and a further $1.2 billion in potential milestone payments. The report cited people familiar with the matter; Reuters said it could not immediately verify it.




